Aiming to target MST1R for cancer therapy, drugs such as tyrosine kinase inhibitors against the tyrosine kinase activity of MST1R and monoclonal antibodies against MST1R are being developed and some of these are under clinical trials or in research phases [27]. Here, MST1R is linked to cancer.